CClinicalTrials.gg
Sign In
CompletedNCT03509324Updated Apr 26, 2018

Effectiveness of Glucose Control, β Cell Function in Response to Short-term Insulin Pump Therapy in Type 2 Diabetes

A Phase 4 interventional study of Insulin LISPRO in Diabetes Mellitus, Type 2, sponsored by Sun Yat-sen University. Completed at 1 site in China. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-04-26.

Sponsored by Sun Yat-sen University · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 1 month after the study started (first participant enrolled Mar 2015, registered Apr 2018).
Phase
Phase 4
Study type
Interventional
Enrollment
67
Allocation
Not applicable
Ages
20 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to investigate and evaluate the significance of intravenous glucose tolerance test in assessment of β-cell function improvement after short course of intensive insulin therapy, trying to illustrate the relationship between fasting plasma glucose and acute insulin release under different stage of type 2 diabetes with poor glycemic control.

02

Conditions studied

  • Diabetes Mellitus, Type 2
03

In context

Diabetes Mellitus

10,925 studies on the registry are indexed under Diabetes Mellitus; 1,318 are open to participants now.

This study's enrollment of 67 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

Sun Yat-sen University is the lead sponsor of 1,644 studies on the registry; 602 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: different course of type 2 diabetes with poor glycemic control

-

Exclusion Criteria:

  • acute complication or severe comorbidities
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Other
    duration of disease

    different duration of disease receive insulin LISPRO

    Drug: Insulin LISPRO

Interventions

  • DrugInsulin LISPRO

    receive short-term insulin pump therapy by using insulin LISPRO, continue treatment for 7 more days when euglycemia achieved

    Also known as: humalog

06

What researchers measure

Primary outcomes

  1. fasting plasma glucose after insulin therapy

    Time frame: 10 hour

07

Study locations

1 site
  • endocrinology department of the first affiliated hospital of Sun Yat-sen University
    Guangzhou, Guangdong 510080, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03509324
Lead sponsor
Sun Yat-sen University
Responsible party
Yanbing Li (Director of Endocrinology Department, Sun Yat-sen University) — Principal investigator
First posted
Apr 26, 2018
Start date
Mar 1, 2015
Primary completion
Jun 30, 2015
Completion
Jun 30, 2015
Last update
Apr 26, 2018

Study contacts

Yanbing Li, MD,PhD
principal investigator · Ministry of Education

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Diabetes Mellitus→

Other studies from this sponsor

Sun Yat-sen University

Start the discussion